Advertisement


Scott Kopetz, MD, PhD, on Metastatic Colorectal Cancer: Quality of Life Results on Encorafenib, Cetuximab, and Binimetinib

2020 Gastrointestinal Cancers Symposium

Advertisement

Scott Kopetz, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase III findings from the BEACON CRC trial, which had demonstrated that the triplet regimen of encorafenib, cetuximab, and binimetinib significantly improved overall survival in patients with a BRAF V600E mutation. The new analysis showed that the regimen also led to substantial improvement in patient-reported quality of life compared with current standard of care (Abstract 8).



Related Videos

Colorectal Cancer

Franck Pagès, MD, PhD, on Stage III Colon Cancer: IDEA Study on a Risk Assessment Tool

Franck Pagès, MD, PhD, of the Hôpital Européen Georges Pompidou, discusses study findings from the prospective IDEA France cohort study of patients with stage III colon cance...

Pancreatic Cancer

Danielle S. Bitterman, MD, on Pancreatic Cancer: Noninvasive Genomic Profiling From Plasma ctDNA

Danielle S. Bitterman, MD, of the Harvard University Radiation Oncology Program and Massachusetts General Hospital, discusses an analysis of genomic and clinical data from 97...

Colorectal Cancer
Immunotherapy

Heinz-Josef Lenz, MD, on Metastatic Colorectal Cancer: Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy

Heinz-Josef Lenz, MD, of USC Norris Comprehensive Cancer Center, discusses how treating microsatellite instability–high/DNA mismatch repair–deficient metastatic colorectal ca...

Hepatobiliary Cancer
Immunotherapy

Peter R. Galle, MD, on Atezolizumab/Bevacizumab vs Sorafenib for Hepatocellular Carcinoma: Patient-Reported Outcomes

Peter R. Galle, MD, of the University Medical Center, Mainz, discusses patient-reported outcomes from this phase III study, which showed the combination of atezolizumab plus ...

Gastrointestinal Cancer

Brian M. Wolpin, MD, on Performance of a Blood-Based Test for the Detection of Multiple Cancers

Brian M. Wolpin, MD, of Dana-Farber Cancer Institute, discusses a noninvasive blood test evaluating methylation of circulating free DNA. In his study, the blood test detected...

Advertisement

Advertisement



Advertisement